Hoffmann-la Roche

This study tested a new drug combination (tiragolumab plus atezolizumab and chemotherapy) against a standard treatment (pembrolizumab plus chemotherapy) in 542 people with advanced non-squamous lung cancer who had not received prior treatment. The goal was to see if the new combo…

This study tested a monthly injection called Mircera in 75 adults with chronic kidney disease and anemia who were not yet on dialysis. The goal was to see if the drug could safely raise and maintain healthy red blood cell levels. Participants received shots once a month for up to…

This study tested a new drug called glofitamab combined with standard chemotherapy (R-ICE) in 43 adults with diffuse large B-cell lymphoma that returned after initial treatment. Participants were eligible for a stem cell transplant or CAR-T therapy. The goal was to see if the com…

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 152 people with advanced liver cancer that could not be removed by surgery and had not been treated with systemic therapy before. The main goal was to check safety, especially serious bleeding side eff…

This study looked at a new way to give two breast cancer drugs (pertuzumab and trastuzumab) as a single shot under the skin instead of through an IV drip. It involved 200 Chinese patients with HER2-positive early breast cancer. The goal was to see if the shot works as well as the…

This study tested the safety of combining the immunotherapy drug atezolizumab with the chemotherapy nab-paclitaxel in 184 people with advanced triple-negative breast cancer that had a specific protein (PD-L1). Participants had not received chemotherapy for their advanced disease.…

This study tested whether people with non-small cell lung cancer prefer getting the drug atezolizumab as a quick shot under the skin (subcutaneous) or as a longer IV drip into a vein. About 179 patients tried both methods and reported which they liked better. The goal was to see …